Tracers / [18F]fallypride
[18F]fallypride
Also written as [18F]Fallypride; [F-18]Fallypride; Fallypride
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 13
What it is
- Compound class
- Radiolabelled substituted benzamide (dopamine D2/D3 receptor antagonist)
- Target / mechanism
- Dopamine D2/D3 receptor ligand PMID 40319441
- Clinical application
- PET imaging of dopamine D2 receptor levels in brain regions in schizophrenia and neuropsychiatric disorders PMID 19251247
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 31891883 2020 Nucl Med Biol |
| AllinOne (AiO) Trasis | vendor cassette | HPLC+SPE | 8 ± 2 yes | >97% | tosylate precursor ABX | 29564391 2017 EJNMMI Radiopharm Chem AllinOne synthesis module — [18F]Fallypride368 ± 22380–320045One vessel, one step, HPLC, SPE |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 59 ± 4% no | 98.4 ± 0.29% | tosyl-fallypride ABX | 40319441 2025 EJNMMI Radiopharm Chem AllinOne synthesis module from Trasis with customized single use cassette operated by the software Trasis Supervision® — yield = 59 ± 4%, not decay corrected |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 31 ± 3% no | 98.9 ± 0.34% | tosyl-fallypride ABX | 40319441 2025 EJNMMI Radiopharm Chem AllinOne synthesis module from Trasis with customized single use cassette operated by the software Trasis Supervision® — yield = 31 ± 3%, not decay corrected |
| Synthra RNplus Synthra | fixed tubing | SPE | 59 ± 4% no | 98.4 ± 0.29% | tosyl-fallypride ABX | 40319441 2025 EJNMMI Radiopharm Chem the Synthra RNplus research module with fixed tubing (RNplus, Synthra, Germany) — yield = 59 ± 4%, not decay corrected |
| Synthra RNplus Synthra | fixed tubing | SPE | 31 ± 3% no | 98.9 ± 0.34% | tosyl-fallypride ABX | 40319441 2025 EJNMMI Radiopharm Chem the Synthra RNplus research module with fixed tubing (RNplus, Synthra, Germany) — yield = 31 ± 3%, not decay corrected |
| — | — | — | — | — | — | 19251247 2009 Biol Psychiatry |
| ELIXYS FLEX/CHEM Sofie Biosciences | — | HPLC | — | — | — | 28443841 2017 Lab Chip synthesized using the ELIXYS radiosynthesizer (Sofie Biosciences, Culver City, CA, USA) |
| iMiDEV PMB-Alcen | vendor cassette | HPLC | 11% | >99% | TsO-fallypride ABX | 39692929 2024 EJNMMI Radiopharm Chem the iMiDEV™ radiosynthesiser — RCYa–17 ± 6%10 ± 1%11% |
| — | — | — | 76 ± 0 % | — | — | 31891883 2020 Nucl Med Biol |
| — | — | HPLC | — | — | — | 29520821 2018 J Labelled Comp Radiopharm |
| — | — | — | — | — | — | 32877862 2020 Appl Radiat Isot |
| — | — | — | 70-90% | — | — | 21989864 2012 Nuklearmedizin |
Need this precursor?We can point you to suppliers for [18F]fallypride, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]fallypride.
Get in touchNotes
Added from reverse module search (stage 6); 15 article(s) with F-18. | Stage 28: added indication(s) neu-huntington, psy-schizophrenia from consolidated missing-rubric review.